Seeking Alpha

(GSK) is making another bolt-on acquisition to strengthen its lineup, agreeing to pay an initial...

(GSK) is making another bolt-on acquisition to strengthen its lineup, agreeing to pay an initial £146M ($227M) to acquire eczema drug Toctino from Swiss biotech Basilea (BPMUF.PK). GSK will pay another £50M if Toctino passes its Phase III trial and receives FDA approval, and royalties on U.S. sales starting three years after launch.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|